欧康维视生物-B(01477.HK):OT-301新药上市注册申请获国家药品监督管理局受理

智通财经
Sep 11
【欧康维视生物-B(01477.HK):OT-301新药上市注册申请获国家药品监督管理局受理】智通财经APP讯,欧康维视生物-B(01477.HK)发布公告,OT-301(NCX 470,格贝前列素)作为降低开角型青光眼或高眼压症患者的眼内压(IOP)疗法的新药上市注册申请(NDA)已获中华人民共和国(中国)国家药品监督管理局药品审评中心受理,并获Mont Blanc试验及Denali试验的数据支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10